Showing 2,672 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Hepatitis B

Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients

News
17 November 2014
Hepatitis C treatment

Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis

News
12 November 2014
Hepatitis & HIV

People living with HIV have high survival rates after liver transplants due to HCC

News
12 November 2014
Hepatitis B

Hepatitis B testing and treatment rates are low among US veterans

News
11 November 2014
New & experimental hepatitis C treatment

Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis

News
11 November 2014
Hepatitis C transmission & prevention

Young drug injectors on opioid maintenance therapy have lower risk of hepatitis C infection

News
11 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
New & experimental hepatitis C treatment

New pill that can cure hepatitis C approved for patients in Scotland

Editor's pick
STV
11 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014
New & experimental hepatitis C treatment

Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

Editor's pick
Achillion press release
10 November 2014
New & experimental hepatitis C treatment

Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead

Editor's pick
Bloomberg
10 November 2014
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection

News
10 November 2014
Hepatitis C treatment

Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants

News
10 November 2014
Hepatitis C treatment

Olysio (simeprevir) approved for use in combination with sofosbuvir

Editor's pick
Johnson & Johnson press release
7 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Hepatitis C symptoms & diagnosis

Half of people with hepatitis C unaware

Editor's pick
Public Health England press release
5 November 2014
Hepatitis C treatment

Bristol-Myers Squibb announces HCV global access plans

Editor's pick
Bristol-Myers Squibb press release
3 November 2014
Hepatitis C transmission & prevention

Opioid Maintenance Therapy Linked to Lower Hepatitis C Rates for People Who Inject Drugs

Editor's pick
HIVandhepatitis.com
29 October 2014
Hepatitis C treatment

Australia's rejection of costly new treatment sofosbuvir a 'death sentence for for Hepatitis C sufferers'

Editor's pick
ABC Online
27 October 2014
New & experimental hepatitis C treatment

AbbVie 3D HCV regimen well-tolerated in PEARL trials

News
24 October 2014